New York, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, ...
The“Global Filgrastim Injection market Research Report 2022 to 2027”, the study focuses on the analysis of historical and current market trends, which serves as a foundation for assessing industry ...
Dublin, Jan. 21, 2022 (GLOBE NEWSWIRE) -- The "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars. Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...
Sandoz announced that Sandoz Japan has received marketing authorization approval for its biosimilar filgrastim (Kyowa Hakko Kirin’s GRAN®). The product, which will be marketed as Filgrastim BS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results